Spectral Medical Secures a $3 Million Funding Boost
In a significant development, Spectral Medical Inc. has successfully secured a $3 million advance through a collaboration with Vantive US Healthcare LLC. This funding serves as a vital resource for Spectral, a company dedicated to enhancing therapeutic treatments for sepsis and septic shock.
Strengthening Financial Position
The recent Tranche B funding is designed to reinforce Spectral's financial stability. The company plans to allocate these funds towards its ongoing efforts in regulatory submissions and commercialization initiatives. With this funding influx, Spectral remains confident that it will not require any further financing for its key upcoming objectives, including U.S. FDA submissions and the commercialization of its product PMX.
Executive Insights
Chris Seto, the Chief Executive Officer of Spectral Medical, expressed his appreciation for the ongoing support provided by Vantive. He emphasized the strategic importance of this non-dilutive capital, which enhances the company’s liquidity and facilitates greater operational flexibility as they pursue their regulatory and commercialization pathways.
Promissory Note Details
According to the terms of the promissory note established with Vantive, the total amount available is up to $10 million, which can be dispensed in up to four tranches. With the latest advance of $3 million, along with the previous $4 million from the Tranche A, the cumulative funding from this arrangement now totals $7 million.
About PMX and its Impact
Spectral Medical’s PMX product is an innovative therapeutic device aimed at treating patients suffering from septic shock by removing harmful endotoxins from the bloodstream. Importantly, PMX is guided by the Endotoxin Activity Assay (EAA™), a clinically validated test that measures endotoxin levels in blood, enhancing treatment effectiveness.
Regulatory Progress and Market Presence
With PMX already approved for use in Japan and Europe, and licensed in Canada, it has seen significant success, with over 360,000 units sold globally. Since obtaining exclusive U.S. rights in 2009 and a distribution agreement for Canada in 2010, Spectral has continued making headway. Notably, in July 2022, the company received Breakthrough Device Designation from the U.S. FDA for PMX, highlighting its potential to address a crucial medical need.
Ongoing Research Initiatives
Currently, Spectral is conducting the Tigris Trial, which aims to validate the effectiveness of PMX in combination with standard care compared to standard care alone. This important study is designed as a randomized trial involving 150 patients, utilizing advanced Bayesian statistics to ensure rigorous results. By focusing on the treatment of endotoxic septic shock, Spectral aims to address a substantial public health challenge.
Contact Information
For more information regarding Spectral Medical’s current projects, stakeholders can reach out to:
Ali Mahdavi, Capital Markets & Investor Relations, Spinnaker Capital Markets Inc., 416-962-3300, am@spinnakercmi.com.
Chris Seto, CEO, Spectral Medical Inc., cseto@spectraldx.com.
Frequently Asked Questions
What is the recent funding amount secured by Spectral Medical?
Spectral Medical has recently secured $3 million from Vantive US Healthcare LLC to support its operations and development plans.
What is PMX and its significance?
PMX is Spectral Medical's therapeutic hemoperfusion device designed to treat septic shock by reducing endotoxins in the bloodstream.
What key milestones does Spectral aim to achieve?
Spectral's main objectives include submitting applications to the U.S. FDA and commercializing PMX.
Who expressed gratitude for the funding support?
Chris Seto, the CEO of Spectral Medical, conveyed appreciation for Vantive's continuous backing.
What is the Tigris Trial?
The Tigris Trial is a confirmatory study that evaluates PMX's effectiveness versus standard care in treating endotoxic septic shock.
